2,2-dimethyl-7-<3-(3-phenylpropyl)-2-thienyl>heptanoic acid | 142422-79-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-dimethyl-7-<3-(3-phenylpropyl)-2-thienyl>heptanoic acid
• 英文别名: 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid；2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid
• CAS: 142422-79-5
• 化学式: C₂₂H₃₀O₂S
• 分子量: 358.545
• InChiKey: QMXLXSYXJOJQSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-<3-(3-phenylpropyl)-2-thienyl>pentanoic acid 在 六甲基磷酰三胺 、 lithium aluminium tetrahydride 、 3-溴丙烯 、 N,N'-羰基二咪唑 、 lithium diisopropyl amide 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 8.0h， 生成 2,2-dimethyl-7-<3-(3-phenylpropyl)-2-thienyl>heptanoic acid
  参考文献：
  名称：

  .omega.-[(.omega.-Arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists

  摘要：

  A series of omega-[(omega-arylalkyl)thienyl]alkanoic acid isomers was prepared and a structure-activity relationship was investigated. These compounds have displayed either LTA, hydrolase inhibition activities or LTB4 receptor binding activities, or both, depending on the relative orientation of the two side chains on the thiophene ring. Whereas the 2,5-isomers specifically exhibited LTA4 hydrolase inhibition, 3,5-isomers displayed both activities. On the other hand, the ''ortho-isomers'' specifically inhibited the binding of the LTB4 to its receptor. The side-chain lengths were also important for an optimal inhibition or binding activity. Substitutions on the terminal aromatic ring or on the thiophene nucleus led to small changes in both activities. The most dramatic effect was obtained by substituting the carboxylic acid side chain in the alpha-position with one or two methyl groups, which substantially enhanced the LTB4 receptor binding activity. In the most favorable case, the alpha,alpha-dimethyl derivative RP66153 was found 20-fold more potent than its linear counterpart.

  DOI：

  10.1021/jm00095a011

文献信息

• Preventive or therapeutic agent for age-related macular degeneration
  申请人：JUNTENDO EDUCATIONAL FOUNDATION

  公开号：US10849954B2

  公开（公告）日：2020-12-01

  To provide a new preventive or therapeutic agent for age-related macular degeneration. The present invention relates to a preventive or therapeutic agent for age-related macular degeneration containing a BLT1 antagonist or a LTB4 biosynthesis inhibitor as an active ingredient. The administration form of the preventive or therapeutic agent for age-related macular degeneration of the present invention includes eye drops, injections, oral agents (tablets, granules, dispersions, capsules), ointments, and creams. The form of these pharmaceutical compositions can be formulated by combining with a pharmaceutically acceptable carrier.

  为老年性黄斑变性提供一种新的预防或治疗剂。 本发明涉及一种老年性黄斑变性的预防或治疗剂，其活性成分含有 BLT1 拮抗剂或 LTB4 生物合成抑制剂。本发明的老年性黄斑变性预防剂或治疗剂的给药形式包括滴眼剂、注射剂、口服剂（片剂、颗粒剂、分散剂、胶囊剂）、软膏和霜剂。这些药物组合物的形式可以通过与药学上可接受的载体结合来配制。
• SUTURES AND ANTI-SCARRING AGENTS
  申请人：Angiotech Pharmaceuticals, Inc.

  公开号：EP1978930A2

  公开（公告）日：2008-10-15
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• electrical devices, anti-scarring agents, and therapeutic compositions
  申请人：Hunter William L.

  公开号：US20090280153A1

  公开（公告）日：2009-11-12

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.